Zentalis to Present at Guggenheim Biotech Summit Amid Key Clinical Milestones
Event summary
- Zentalis Pharmaceuticals will participate in Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11, 2026.
- Management will join a fireside discussion at 3:30 p.m. ET in New York.
- The company is advancing azenosertib, a first-in-class WEE1 inhibitor, for ovarian cancer and other tumor types.
- Zentalis aims to equip physicians with a targeted, non-chemo, orally available medicine.
- Live webcast and archived recording will be available for 30 days post-event.
The big picture
Zentalis' participation in Guggenheim's Biotech Summit comes as the company advances its lead candidate, azenosertib, through critical clinical stages. The focus on biomarker-driven strategies aligns with broader industry trends toward precision oncology, where targeted therapies are increasingly replacing traditional chemotherapy. The company's ability to secure regulatory approval and commercialize azenosertib will be pivotal in determining its long-term market position.
What we're watching
- Clinical Progress
- The pace at which Zentalis advances DENALI Part 2a dose confirmation and topline readout from DENALI Part 2.
- Regulatory Strategy
- Whether DENALI Part 2 data will support an accelerated approval pathway for azenosertib.
- Market Positioning
- How Zentalis differentiates azenosertib in the competitive landscape of ovarian cancer treatments.
Related topics